Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 TranscriptSeeking Alpha • 03/13/26
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/10/26
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA DecisionThe Motley Fool • 03/09/26
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity SalesZacks Investment Research • 02/24/26
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be OvervaluedSeeking Alpha • 02/23/26
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/23/26
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/23/26
AI, Clean Energy & Health Stocks: The Big Winners in a Multipolar 2026Zacks Investment Research • 02/20/26
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.GlobeNewsWire • 02/17/26
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/16/26
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23GlobeNewsWire • 01/27/26
Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength?Zacks Investment Research • 01/21/26
Axsome Therapeutics Begins Phase III Study on AXS-14 for FibromyalgiaZacks Investment Research • 01/16/26
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-TermZacks Investment Research • 01/15/26
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product RevenueGlobeNewsWire • 01/12/26